2005-2024 Yılları Arasında Serebral Palsi’de Botulinum Toksinin Bibliyometrik Analizi

Yıl 2025, Cilt: 47 Sayı: 5, 803 - 815, 04.09.2025

Gizem Sarıçimen , Ayşe Merve Çıracıoğlu

https://doi.org/10.20515/otd.1748777

Öz

Bu çalışma, 2005–2024 yılları arasında serebral palside (SP) botulinum toksin A (BoNT‑A) uygulamalarıyla ilgili literatürü değerlendiren kapsamlı bir bibliyometrik analiz sunmaktadır. Web of Science Core Collection veri tabanında yapılan tarama sonucunda 690 yayın (550 araştırma makalesi, 140 derleme) incelenmiştir. Yayın sayısında yıllar içinde genel bir artış gözlenmiş, 2018’de en yüksek üretim gerçekleşmiş, 2020–2021’de geçici bir düşüş yaşanmıştır. Araştırmalara en fazla katkı sağlayan ülkeler ABD, Avustralya ve İtalya olurken, Avustralya en yüksek ortalama atıf oranına ulaşmıştır. En üretken yazar Desloovere K, en çok atıf alan yazar ise Graham HK olarak belirlenmiştir. Anahtar kelime analizinde “cerebral palsy”, “botulinum toxin”, “spasticity” merkezde yer almış; “rehabilitation”, “gait analysis” ve “quality of life” gibi kavramlar ön plana çıkmıştır. Son yıllarda “ultrasound” ve “electromyography” gibi teknolojik kavramların kullanımı artmıştır. Ayrıca “sialorrhea” tedavisine yönelik intraglandüler BoNT‑A uygulamaları vurgulanmıştır. Çalışmada, üst ekstremitede BoNT‑A’nın fonksiyonel kazanımlar için rehabilitasyonla birlikte uygulanmasının önerildiği belirtilmiştir. Literatürde uzun dönem etkinlik verilerinin sınırlı olduğu ve çok merkezli, prospektif çalışmalara ihtiyaç duyulduğu vurgulanmıştır.

Anahtar Kelimeler

bibliyometrik analiz , botulinum toksin , serebral palsi , spastisite

A Bibliometric Analysis of Botulinum Toxin in Cerebral Palsy from 2005 to 2024

Öz

This study presents a comprehensive bibliometric analysis of the literature on botulinum toxin A (BoNT‑A) applications in cerebral palsy (CP) between 2005 and 2024. A search conducted in the Web of Science Core Collection identified 690 publications (550 original research articles and 140 reviews). An overall increase in publication output was observed over the years, peaking in 2018, with a temporary decline noted in 2020–2021. The United States, Australia, and Italy were the leading contributors, with Australia achieving the highest average citation rate. Desloovere K was identified as the most productive author, while Graham HK received the highest number of citations. Keyword analysis revealed that “cerebral palsy,” “botulinum toxin,” and “spasticity” were central themes, while concepts such as “rehabilitation,” “gait analysis,” and “quality of life” also stood out. In recent years, the use of technological terms such as “ultrasound” and “electromyography” has increased. In addition, intraglandular BoNT‑A applications for the treatment of “sialorrhea” have been highlighted. The study also noted that BoNT‑A in the upper limb is recommended to be combined with rehabilitation in order to achieve functional gains. The literature emphasizes that data on long‑term efficacy remain limited and that there is a need for multicenter, prospective studies.

Anahtar Kelimeler

bibliometric analysis , botulinum toxin , cerebral palsy , spasticty

Etik Beyan

Since the data in this study were derived from previous studies, ethics committee approval was waived.

Destekleyen Kurum

This study received no external funding.

Teşekkür

-

Kaynakça

• 1. Vitrikas K, Dalton H, Breish D. Cerebral Palsy: An Overview. Am Fam Physician. 2020;101(4):213-20.
• 2. Sainz-Pelayo MP, Albu S, Murillo N, Benito-Penalva J. Spasticity in neurological pathologies. An update on the pathophysiological mechanisms, advances in diagnosis and treatment. Rev Neurol. 2020;70(12):453-60.
• 3. Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol. 2000;42(12):816–24.
• 4. Vitrikas K, Dalton H, Breish D. Cerebral Palsy: An Overview. Am Fam Physician. 2020;101(4):213-20.
• 5. Keles CSK, Ates F. Botulinum toxin intervention in cerebral palsy-induced spasticity management: projected and contradictory effects on skeletal muscles. Toxins. 2022;14(11):772.
• 6. Strobl W, Theologis T, Brunner R, Kocer S, Viehweger E, Pascual-Pascual I, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins. 2015;7(5):1629-48.
• 7. Gantelius S, Vikerfors S, Edqvist JJ, von Walden F, Hagströmer M, Pontén E. Time-matched accelerometers on limbs and waist in children with CP give new insights into real-life activities after botulinum toxin treatment: A proof of concept study. J Pediatr Rehabil Med. 2023;16(1):125-37.
• 8. Mukherjee D, Lim WM, Kumar S, Donthu N. Guidelines for advancing theory and practice through bibliometric research. J Bus Res. 2022;148:101-15.
• 9. Szomszor M, Adams J, Fry R, Gebert C, Pendlebury DA, Potter RWK, et al. Interpreting Bibliometric Data. Front Res Metr Anal. 2021;9(5):628703.
• 10. Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: How great is the impact? Scientometrics. 2015;105(3):1809-31.
• 11. Manoj Kumar L, George RJ, P S A. Bibliometric Analysis for Medical Research. Indian J Psychol Med. 2023;45(3):277-82.
• 12. Xiong HY, Zhang ZJ, Wang XQ. Bibliometric Analysis of Research on the Comorbidity of Pain and Inflammation. Pain Res Manag. 2021;2021:6655211.
• 13. AlRyalat SAS, Malkawi LW, Momani SM. Comparing bibliometric analysis using PubMed, Scopus, and Web of Science databases. J Vis Exp. 2019;24(152):58494.
• 14. Moral-Muñoz JA, Herrera-Viedma E, Santisteban-Espejo A, Cobo MJ. Software tools for conducting bibliometric analysis in science: An up-to-date review. Profesional de la Información. 2020;29(1).
• 15. Aria M, Cuccurullo C. Bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959–75.
• 16. Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55(10):885-910.
• 17. Novak I, Morgan C, Fahey M, Finch-Edmondson M, Galea C, Hines A, et al. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020;;20(2):3.
• 18. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691-8.
• 19. Sadowska M, Sarecka-Hujar B, Kopyta I. Cerebral Palsy: Current Opinions on Definition, Epidemiology, Risk Factors, Classification and Treatment Options. Neuropsychiatr Dis Treat. 2020;16:1505-18.
• 20. Sakzewski L, Ziviani J, Boyd RN. Efficacy of upper limb therapies for unilateral cerebral palsy: a meta-analysis. Pediatrics. 2014;133(1):175-204.
• 21. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, Andersen GL, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010;14(1):45-66.
• 22. Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336-43.
• 23. Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev. 2010;2010(1):CD003469.
• 24. Love SC, Novak I, Kentish M, Desloovere K, Heinen F, Molenaers G, et al. Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010;17(2):9-37.
• 25. Barber L, Hastings-Ison T, Baker R, Barrett R, Lichtwark G. Medial gastrocnemius muscle volume and fascicle length in children aged 2 to 5 years with cerebral palsy. Dev Med Child Neurol. 2011;53(6):543-8.
• 26. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214-23.
• 27. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206-7.
• 28. Graham HK, Aoki KR, Autti-Rämö I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11(1):67-79.
• 29. Koman LA, Mooney III JF, Smith BP, Walker F, Leon JM, BOTOX Study Group. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop. 2000;20(1):108.
• 30. Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8-14.
• 31. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et a. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010;14(1):45-66.
• 32. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child. 2000;83(6):481-7.
• 33. Love SC, Novak I, Kentish M, Desloovere K, Heinen F, Molenaers G, et al.; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010;2:9-37.
• 34. Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop. 1993;13(4):489-95.
• 35. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol. 1994;36(5):386-96.
• 36. Hu Y, Zheng Y, Yang Y, Fang W, Huang M, Li D, et al. J. A bibliometric analysis of cerebral palsy from 2003 to 2022. Front Neurol. 2024;15:1292587.
• 37. Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lancet. 2004;363(9421):1619-31.
• 38. Facciorusso S, Spina S, Picelli A, Baricich A, Francisco GE, Molteni F, et al. The Role of Botulinum Toxin Type-A in Spasticity: Research Trends from a Bibliometric Analysis. Toxins (Basel). 2024;16(4):184.
• 39. Multani I, Manji J, Hastings-Ison T, Khot A, Graham K. Botulinum Toxin in the Management of Children with Cerebral Palsy. Paediatr Drugs. 2019;21(4):261-81.
• 40. Büyükavcı R, Büyükavcı MA. Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy. Acta Neurol Belg. 2018;118(3):429-33.
• 41. Jardon M, Nguyen J, Casaletto E, Ko L, Wolff A, Daluiski A, et al. Utilization of shear wave elastography to quantify and predict response to upper extremity botulinum toxin injections in patients with cerebral palsy: A pilot study. Clin Neurol Neurosurg. 2023;230:107798.
• 42. Fry NR, Gough M, Shortland AP. Three-dimensional realisation of muscle morphology and architecture using ultrasound. Gait Posture. 2004;20(2):177-82.
• 43. Yi YG, Jang DH, Lee D, Oh JY, Han MH. Botulinum Toxin Injection in Children with Hemiplegic Cerebral Palsy: Correction of Growth through Comparison of Treated and Unaffected Limbs. Toxins (Basel). 2019;11(12):688.
• 44. Porte M, Chaléat-Valayer E, Patte K, D'Anjou MC, Boulay C, Laffont I. Relevance of intraglandular injections of Botulinum toxin for the treatment of sialorrhea in children with cerebral palsy: a review. Eur J Paediatr Neurol. 2014;18(6):649-57.
• 45. Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope. 2002;112(1):73-81.
• 46. Farag SM, Mohammed MO, El-Sobky TA, ElKadery NA, ElZohiery AK. Botulinum Toxin A Injection in Treatment of Upper Limb Spasticity in Children with Cerebral Palsy: A Systematic Review of Randomized Controlled Trials. JBJS Rev. 2020;8(3):e0119.
• 47. Rameckers EA, Speth LA, Duysens J, Vles JS, Smits-Engelsman BC. Botulinum toxin-a in children with congenital spastic hemiplegia does not improve upper extremity motor-related function over rehabilitation alone: a randomized controlled trial. Neurorehabil Neural Repair. 2009;23(3):218-25.